Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials

被引：0
|
作者：
Folprecht, G.
Seymour, M. T.
Saltz, L.
Douillard, J. Y.
Stephens, R. J.
Van Cutsem, E.
Rougier, P.
Maughan, T. S.
Koehne, C. H.
机构：
[1] Univ Hosp Dresden, Dresden, Germany
[2] Cookridge Hosp, Leeds, W Yorkshire, England
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Ctr R Gauducheau, Nantes, France
[5] MRC Clin Trials Unit, London, England
[6] Univ Hosp Gasthuisberg, Leuven, Belgium
[7] Hop Ambroise Pare, Boulogne, France
[8] Velindre Hosp, Cardiff, S Glam, Wales
[9] Klinikum Oldenburg GGmbH, Oldenburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4071
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SECOND-LINE CHEMOTHERAPY AFTER FIRST-LINE IRINOTECAN, OXALIPLATIN AND 5-FU/LV (FOLFOXIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Marcucci, L.
    Cupini, S.
    Masi, G.
    Allegrini, G.
    Cerri, E.
    Loupakis, F.
    Ricci, S.
    Brunetti, I.
    Fontana, E.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 60 - 60
  • [32] FIRST LINE CHEMOTHERAPY (FLC) USING IRINOTECAN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFIRI) COMBINED WITH BEVACIZUMAB IN MEATASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 62 - 62
  • [33] CONTROLLED RANDOMIZED EVALUATION OF COMBINED MODALITY THERAPY (5000 RAD, 5-FU + MECCNU) VS 5-FU + MECCNU ALONE FOR LOCALLY UNRESECTABLE GASTRIC CANCER
    SCHEIN, PS
    CHILDS, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 329 - 329
  • [34] RANDOMIZED TRIAL OF MELPHALAN PLUS 5-FLUOROURACIL (5-FU) VERSUS METHYL-CCNU PLUS 5-FU IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    BERMAN, R
    GILES, GR
    MALHOTRA, A
    BIRD, GG
    GAJJAR, PD
    BUNCH, GA
    HALL, R
    CANCER TREATMENT REPORTS, 1978, 62 (03): : 457 - 459
  • [35] Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials
    Goldberg, RM
    Erlichman, C
    ONCOLOGY-NEW YORK, 1998, 12 (08): : 59 - 63
  • [36] Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    Saunders, MP
    Hogg, M
    Carrington, B
    Sjursen, AM
    Allen, J
    Beech, J
    Swindell, R
    Valle, JW
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1447 - 1452
  • [37] Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    M P Saunders
    M Hogg
    B Carrington
    A-M Sjursen
    J Allen
    J Beech
    R Swindell
    J W Valle
    British Journal of Cancer, 2004, 91 : 1447 - 1452
  • [38] A randomised phase-ill study comparing weekly folinic acid (FA) and highdose B-Fluorouracil (5-FU) with monthly 5-FU/FA d 1-5 in untreated patients with metastatic colorectal carcinoma (CRC)
    Weh, HJ
    Zschaber, R
    Braumann, D
    Hoelzer, P
    Hoffmann, R
    Becker, K
    Kleeberg, UR
    Pompecki, R
    Hoffknecht, M
    Benner, A
    Hossfeld, DK
    ANNALS OF ONCOLOGY, 1998, 9 : 33 - 33
  • [39] Phase I study of 'Tomudex' combined with protracted infusion of 5-FU in patients (pts) with metastatic colorectal cancer
    Mayer, S
    Harstrick, A
    Muller, C
    Dohmen, D
    Hilger, R
    Scheulen, ME
    Wilke, H
    Seeber, S
    ANNALS OF ONCOLOGY, 1998, 9 : 165 - 165
  • [40] PROTRACTED INFUSION OF 5-FU WITH WEEKLY LOW-DOSE CISPLATIN AS 2ND-LINE THERAPY IN PATIENTS WITH METASTATIC COLORECTAL-CANCER WHO HAVE FAILED 5-FU MONOTHERAPY
    AHLGREN, JD
    TROCKI, O
    GULLO, JJ
    GOLDBERG, R
    MUIR, WA
    SISK, R
    SCHACTER, L
    CANCER INVESTIGATION, 1991, 9 (01) : 27 - 33
12345